School of Medicine
Showing 1-10 of 16 Results
Assistant Professor of Cardiothoracic Surgery at the Lucile Salter Packard Children's Hospital and at the Stanford University Medical Center
Current Research and Scholarly Interests Our lab aims to understand the biomechanics that govern a wide spectrum of congenital heart defects, and how those biomechanics change with contemporary operative repair strategies. We simulate operations virtually via CFD, and in ex vivo and in vivo animal models, and analyze how the changes we make alter fluid flow, pressure, and stresses throughout the system. We hope that these experiments can impact and optimize existing techniques that translate quickly to the operating room.
Sean Mackey, M.D., Ph.D.
Redlich Professor, Professor of Anesthesiology, Perioperative, and Pain Medicine and, by courtesy, of Neurology at the Stanford University Medical Center
Current Research and Scholarly Interests Multiple NIH funded projects to characterize CNS mechanisms of human pain. Comparative effectiveness of cognitive behavioral therapy and chronic pain self-management within the context of opioid reduction (PCORI funded). Single session pain catastrophizing treatment: comparative efficacy & mechanisms (NIH R01). Development and implementation of an open-source learning healthcare system, CHOIR (http://choir/stanford.edu), to optimize pain care and innovative research in real-world patients.
Professor (Research) of Microbiology and Immunology
Current Research and Scholarly Interests I'm interested in immune monitoring of T cell responses to chronic pathogens and cancer, and the correlation of T cell response signatures with disease protection.
Professor of Medicine (Cardiovascular Medicine) at the Stanford University Medical Center
Bio Clinical Focus: Cardiovascular Medicine
My primary research interest is the design and conduct of multicenter clinical trials and analyses of important clinical cardiac issues using large patient databases. My research focuses on novel anticoagulation agents for the treatment of acute coronary syndromes and atrial fibrillation, the study of agents targeted to protect the myocardium during reperfusion therapy for acute myocardial infarction, and the evaluation of cardiovascular safety of diabetic therapies. I am also interested in the methodology of clinical trials. Current research activities include standardization of the definition of myocardial infarction used in clinical trials, the adjudication of suspected clinical endpoint events by Clinical Event Committees (CEC), and the efficient operational conduct of large multinational clinical trials.
Administrative Focus: Vice Chair of Clinical Research in the Department of Medicine and Member of the Stanford IRB
1985 Stanford University, BS Chemistry
1989 University of Washington, MD
1993 University of Arizona, Internship/Residency/Chief Residency
1996 Duke University, Fellowship in Cardiology
1996 Duke University, Faculty in Cardiology
2013 Stanford University, Vice Chair of Clinical Research, Department of Medicine
Associate Professor of Pediatrics (Cardiology) and of Bioengineering
Current Research and Scholarly Interests The Cardiovascular Biomechanics Computation Lab at Stanford develops novel computational methods for the study of cardiovascular disease progression, surgical methods, and medical devices. We have a particular interest in pediatric cardiology, and use virtual surgery to design novel surgical concepts for children born with heart defects.
Professor of Medicine (Cardiovascular)
Bio Dr. Mercola is Professor of Medicine and Professor in the Stanford Cardiovascular Institute. He completed postdoctoral training at the Dana-Farber Cancer Institute and Harvard Medical School, was on the faculty in the Department of Cell Biology at Harvard Medical School for 12 years, and later at the Sanford-Burnham-Prebys Institute and Department of Bioengineering at the University of California, San Diego before relocating to Stanford in 2015.
Prof. Mercola is known for identifying many of the factors that are responsible for inducing and forming the heart, including the discovery that Wnt inhibition is a critical step in cardiogenesis that provided the conceptual basis and reagents for the large-scale production of cardiovascular tissues from pluripotent stem cells. He has collaborated with medicinal chemists, optical engineers and software developers to pioneer the use of patient iPSC-cardiomyocytes for disease modeling, safety pharmacology and drug development. His academic research is focused on developing and using quantitative high throughput assays of patient-specific cardiomyocyte function to discover druggable targets for preserving contractile function in heart failure and promoting regeneration following ischemic injury. He co-established drug screening and assay development at the Conrad Prebys Drug Discovery Center (San Diego), which operated as one of 4 large screening centers of the US National Institutes of Health (NIH) Molecular Libraries screening initiative and continues as one of the largest academic drug screening centers.
Prof. Mercola received an NIH MERIT award for his work on heart formation, and authored over 130 papers. He holds numerous patents, including describing the invention of the first engineered dominant negative protein and small molecules for stem cell and cancer applications. He serves on multiple editorial and advisory boards, including Vala Sciences,, Regencor, The Ted Rogers Centre for Heart Research and the Human Biomolecular Research Institute. His laboratory is funded by the National Institutes of Health (NIH), California Institute for Regenerative Medicine, the PLN Foundation and the Fondation Leducq.
The George D. Smith Professor in Translational Medicine
Current Research and Scholarly Interests Two areas: 1. Using rationally-designed peptide inhibitors to study protein-protein interactions in cell signaling. Focus: protein kinase C in heart and large GTPases regulating mitochondrial dynamics in neurodegdenration. 2. Using small molecules (identified in a high throughput screens and synthetic chemistry) as activators and inhibitors of aldehyde dehydrogenases, a family of detoxifying enzymes, and glucose-6-phoshate dehydrogenase, in normal cells and in models of human diseases.